Structures and mechanisms of enzymes in the leukotriene cascade

Biochimie

Volumn 92, Issue 6, 2010, Pages 676-681

  Rinaldo Matthis, Agnes ^a   Haeggström, Jesper Z ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 Lipoxygenase; Arachidonic acid; Leukotriene A4 hydrolase; Leukotriene C4 synthase; Leukotrienes; Phospholipase A2

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; ENZYME INHIBITOR; LEUKOTRIENE; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE A4 HYDROLASE INHIBITOR; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE C4 SYNTHASE; MONTELUKAST; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON;

ASTHMA; BIOSYNTHESIS; BRONCHOSPASM; CARDIOVASCULAR INFLAMMATION; CATALYSIS; CLINICAL TRIAL; DRUG DESIGN; ENZYME MECHANISM; ENZYME STRUCTURE; HEART INFARCTION; HUMAN; INNATE IMMUNITY; NONHUMAN; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOOTH MUSCLE CONTRACTION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; EPOXIDE HYDROLASES; GLUTATHIONE TRANSFERASE; HUMANS; INFLAMMATION MEDIATORS; LEUKOTRIENES; MODELS, MOLECULAR; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

EID: 77953293797     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.01.010     Document Type: Review

References (57)

1. Peters-Golden M., Henderson W.R. Leukotrienes. N. Engl. J. Med. 2007, 357:1841-1854.
2. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999, 340:197-206.
3. Burke J.E., Dennis E.A. Phospholipase A2 structure/function mechanism, and signaling. J. Lipid Res. 2009, 50(Suppl.):S237-S242.
4. Schaloske R.H., Dennis E.A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761:1246-1259.
5. Uozumi N., Kume K., Nagase T., et al. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 1997, 390:618-622.
6. Bonventre J.V., Huang Z., Taheri M.R., et al. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997, 390:622-625.
7. Gijon M.A., Spencer D.M., Siddiqi A.R., Bonventre J.V., Leslie C.C. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium: novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J. Biol. Chem. 2000, 275:20146-20156.
8. Lambeau G., Gelb M.H. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu. Rev. Biochem. 2008, 77:495-520.
9. Sato H., Taketomi Y., Isogai Y., Masuda S., Kobayashi T., Yamamoto K., Murakami M. Group III secreted phospholipase A2 transgenic mice spontaneously develop inflammation. Biochem. J. 2009, 421:17-27.
10. Edwards S.H., Thompson D., Baker S.F., Wood S.P., Wilton D.C. The crystal structure of the H48Q active site mutant of human group IIA secreted phospholipase A2 at 1.5 Å resolution provides an insight into the catalytic mechanism. Biochemistry 2002, 41:15468-15476.
11. Schievella A.R., Regier M.K., Smith W.L., Lin L.L. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J. Biol. Chem. 1995, 270:30749-30754.
12. Xu G.Y., McDonagh T., Yu H.A., Nalefski E.A., Clark J.D., Cumming D.A. Solution structure and membrane interactions of the C2 domain of cytosolic phospholipase A2. J. Mol. Biol. 1998, 280:485-500.
13. Leslie C., Channon J.Y. Anionic phospholipids stimulate an arachidonoyl-hydrolyzing phospholipase A2 from macrophages and reduce the calcium requirement for activity. Biochim. Biophys. Acta 1990, 1045:261-270.
14. Lamour N.F., Subramanian P., Wijesinghe D.S., Stahelin R.V., Bonventre J.V., Chalfant C.E. Ceramide 1-phosphate is required for the translocation of group IVA cytosolic phospholipase A2 and prostaglandin synthesis. J. Biol. Chem. 2009, 284:26897-26907.
15. Subramanian P., Vora M., Gentile L.B., Stahelin R.V., Chalfant C.E. Anionic lipids activate group IVA cytosolic phospholipase A2 via distinct and separate mechanisms. J. Lipid Res. 2007, 48:2701-2708.
16. Gillmor S.A., Villaseñor A., Fletterick R., Sigal E., Browner M.F. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat. Struct. Biol. 1997, 4:1003-1009.
17. Neau D.B., Gilbert N.C., Bartlett S.G., Boeglin W.E., Brash A.R., Newcomer M.E. The 1.85 structure of an 8R-Lipoxygenase suggests a general model for lipoxygenase product specificity. Biochemistry 2009, 48:7906-7915.
18. Hammarberg T., Provost P., Persson B., Rådmark O. The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J. Biol. Chem. 2000, 275:38787-38793.
19. Chen X.S., Funk C.D. The N-terminal " beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation. J. Biol. Chem. 2001, 276:811-818.
20. Buczynski M.W., Stephens D.L., Bowers-Gentry R.C., Grkovich A., Deems R.A., Dennis E.A. TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells. J. Biol. Chem. 2007, 282:22834-22847.
21. Hammarberg T., Kuprin S., Rådmark O., Holmgren A. EPR investigation of the active site of recombinant human 5-lipoxygenase: inhibition by selenide. Biochemistry 2001, 40:6371-6378.
22. Skrzypczak-Jankun E., Amzel L.M., Kroa B.A., Funk M.O. Structure of soybean lipoxygenase L3 and a comparison with its L1 isoenzyme. Proteins 1997, 29:15-31.
23. Rakonjac M., Fischer L., Provost P., Werz O., Steinhilber D., Samuelsson B., Rådmark O. Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13150-13155.
24. Pande A.H., Qin S., Tatulian S.A. Membrane fluidity is a key modulator of membrane binding, insertion, and activity of 5-lipoxygenase. Biophys. J. 2005, 88:4084-4094.
25. Woods J.W., Evans J.F., Ethier D., Scott S., Vickers P.J., Hearn L., Heibein J.A., Charleson S., Singer I.I. 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J. Exp. Med. 1993, 178:1935-1946.
26. Folco G., Murphy R.C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 2006, 58:375-388.
27. O. Rådmark, B. Samuelsson, Regulation of 5-lipoxygenase enzyme activity, 338 (2005) 102-110.
28. Zhao L., Moos M.P., Gräbner R., et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med. 2004, 10:966-973.
29. Chen X.S., Sheller J.R., Johnson E.N., Funk C.D. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994, 372:179-182.
30. Berger W., De Chandt M.T.M., Cairns C.B. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 2007, 61:663-676.
31. Mancini J.A., Abramovitz M., Cox M.E., et al. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 1993, 318:277-281.
32. Plante H., Picard S., Mancini J., Borgeat P. 5-Lipoxygenase-activating protein homodimer in human neutrophils: evidence for a role in leukotriene biosynthesis. Biochem. J. 2006, 393:211-218.
33. Byrum R.S., Goulet J.L., Griffiths R.J., Koller B.H. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses. J. Exp. Med. 1997, 185:1065-1075.
34. Griffiths R.J., Smith M.A., Roach M.L., et al. Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice. J. Exp. Med. 1997, 185:1123-1129.
35. Ferguson A.D., McKeever B.M., Xu S., et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007, 317:510-512.
36. Mandal A.K., Jones P.B., Bair A.M., et al. The nuclear membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20434-20439.
37. A. Tavridou, V.G. Manolopoulos, Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369, Expert Opin Ther Pat. (2009).
38. Haeggström J.Z. Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J. Biol. Chem. 2004, 279:50639-50642.
39. Thunnissen M.M., Nordlund P., Haeggström J.Z. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat. Struct. Biol. 2001, 8:131-135.
40. Andberg M.B., Hamberg M., Haeggström J.Z. Mutation of tyrosine 383 in leukotriene A4 hydrolase allows conversion of leukotriene A4 into 5S,6S-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid. Implications for the epoxide hydrolase mechanism. J. Biol. Chem. 1997, 272:23057-23063.
41. Kester W.R., Matthews B.W. Crystallographic study of the binding of dipeptide inhibitors to thermolysin: implications for the mechanism of catalysis. Biochemistry 1977, 16:2506-2516.
42. Wetterholm A., Medina J.F., Rådmark O., Shapiro R., Haeggström J.Z., Vallee B.L., Samuelsson B. Leukotriene A4 hydrolase: abrogation of the peptidase activity by mutation of glutamic acid-296. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:9141-9145.
43. Tholander F., Muroya A., Roques B.P., Fournié-Zaluski M.C., Thunnissen M.M., Haeggström J.Z. Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and inhibitor design. Chem. Biol. 2008, 15:920-929.
44. Evans J.F., Nathaniel D.J., Zamboni R.J., Ford-Hutchinson A.W. Leukotriene A3. A poor substrate but a potent inhibitor of rat and human neutrophil leukotriene A4 hydrolase. J. Biol. Chem. 1985, 260:10966-10970.
45. Ohishi N., Izumi T., Minami M., et al. Leukotriene A4 hydrolase in the human lung. Inactivation of the enzyme with leukotriene A4 isomers. J. Biol. Chem. 1987, 262:10200-10205.
46. Yokomizo T., Izumi T., Chang K., Takuwa Y., Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620-624.
47. Yokomizo T., Kato K., Terawaki K., Izumi T., Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 2000, 192:421-432.
48. Davies D.R., Mamat B., Magnusson O.T., et al. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J. Med. Chem. 2009, 52:4694-4715.
49. Martinez Molina D., Eshaghi S., Nordlund P. Catalysis within the lipid bilayer-structure and mechanism of the MAPEG family of integral membrane proteins. Curr. Opin. Struct. Biol. 2008, 18:442-449.
50. Martinez Molina D., Wetterholm A., Kohl A., McCarthy A.A., Niegowski D., Ohlson E., Hammarberg T., Eshaghi S., Haeggström J.Z., Nordlund P. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 2007, 448:613-616.
51. Ago H., Kanaoka Y., Irikura D., Lam B.K., Shimamura T., Austen K.F., Miyano M. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 2007, 448:609-612.
52. Jegerschöld C., Pawelzik S.C., Purhonen P., Bhakat P., Gheorghe K.R., Gyobu N., Mitsuoka K., Morgenstern R., Jakobsson P.J., Hebert H. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11110-11115.
53. Hammarberg T., Hamberg M., Wetterholm A., Hansson H., Samuelsson B., Haeggström J.Z. Mutation of a critical arginine in microsomal prostaglandin E synthase-1 shifts the isomerase activity to a reductase activity that converts prostaglandin H2 into prostaglandin F2alpha. J. Biol. Chem. 2009, 284:301-305.
54. Gupta N., Nicholson D.W., Ford-Hutchinson A.W. Demonstration of cell-specific phosphorylation of LTC4 synthase. FEBS Lett. 1999, 449:66-70.
55. Heise C.E., O'Dowd B.F., Figueroa D.J., et al. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 2000, 275:30531-30536.
56. Lynch K.R., O'Neill G.P., Liu Q. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999, 399:789-793.
57. Maekawa A., Kanaoka Y., Xing W., Austen K.F. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16695-16700.